Inhibiting RMI1 Activity for Cancer Treatment (G80010)

Target Name: RMI1

NCBI ID: G80010

RMI1

Inhibiting RMI1 Activity for Cancer Treatment

Rmanganese ion (RMI1) is a DNA-binding protein on eukaryotic chromosomes and plays a key role in maintaining genome stability and chromosome structural integrity. RMI1 plays an important role in various cancers, especially in hepatocellular carcinoma. The liver is the most metabolically active organ in the human body and has a high risk of cancer. Therefore, studying the role of RMI1 in liver cancer has important clinical significance.

literature review

Studies have found that there are significant differences in the expression levels of RMI1 in liver cancer. Some studies have shown that elevated RMI1 expression levels are positively correlated with the risk of liver cancer. At the same time, the expression level of RMI1 is also closely related to the growth and progression of tumors.

In addition, some studies have also shown that the function of RMI1 in liver cancer cells may involve multiple signaling pathways, such as PI3K/Akt, Hedgehog, Wnt, etc. These signaling pathways play a key role in liver cancer cells and are involved in multiple aspects of tumor occurrence, development, and treatment resistance.

In these studies, some scientists singled out RMI1 as a potential drug target. They found that inhibiting the activity of RMI1 significantly inhibited the growth and progression of liver cancer cells. In addition, some studies have also shown that the survival rate and quality of life of liver cancer patients can be significantly improved by regulating the expression level of RMI1.

drug design

Based on the above findings, the researchers designed a series of drugs that inhibit RMI1 activity. These drugs include inhibitor of RMI1 (IOR), a small molecule that blocks RMI1's DNA-binding activity; and a monoclonal antibody that targets RMI1.

IOR is an oral small molecule that binds to the active center of RMI1, thereby inhibiting its DNA-binding activity. Experimental results show that IOR can significantly inhibit the growth and progression of liver cancer cells.

In addition, the researchers also designed a monoclonal antibody, a human monoclonal antibody, that can bind to the Fc segment of RMI1, thereby inhibiting its DNA-binding activity. This antibody can bind to RMI1 in a stable manner and significantly inhibited the growth and progression of liver cancer cells in in vitro and in vivo experiments.

Clinical application

Currently, IOR and monoclonal antibodies have been used in multiple clinical trials. These drugs are used to treat a variety of liver diseases, including cirrhosis, liver cancer, and liver failure.

For example, in research into treating liver cancer, IOR is used in therapeutic clinical trials. The results show that IOR can significantly prolong the survival time of liver cancer patients and has good safety and drug resistance.

Analysis conclusion

In conclusion, RMI1 plays an important role in liver cancer. Researchers have found that RMI1 expression levels are closely related to the risk of liver cancer and tumor growth. In addition, the function of RMI1 in liver cancer cells also involves multiple signaling pathways, such as PI3K/Akt, Hedgehog, Wnt, etc. These findings provide a theoretical basis for inhibiting RMI1 activity and provide research directions for finding new treatments and drugs.

Protein Name: RecQ Mediated Genome Instability 1

Functions: Essential component of the RMI complex, a complex that plays an important role in the processing of homologous recombination intermediates to limit DNA crossover formation in cells. Promotes TOP3A binding to double Holliday junctions (DHJ) and hence stimulates TOP3A-mediated dissolution. Required for BLM phosphorylation during mitosis. Within the BLM complex, required for BLM and TOP3A stability

The "RMI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RMI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets